journal article·2023-09Open access

GART Functions as a Novel Methyltransferase in the RUVBL1/β‐Catenin Signaling Pathway to Promote Tumor Stemness in Colorectal Cancer

Chao Tang, Mengying Ke, Xichao Yu, Shanliang Sun, Xian Luo, Xin Liu, Yanyan Zhou, Ze Wang, Xing Cui, Chunyan Gu, Ye Yang

Advanced Science· Volume 10· Issue 25

Abstract

Abstract Tumor stemness is associated with the recurrence and incurability of colorectal cancer (CRC), which lacks effective therapeutic targets and drugs. Glycinamide ribonucleotide transformylase (GART) fulfills an important role in numerous types of malignancies. The present study aims to identify the underlying mechanism through which GART may promote CRC stemness, as to developing novel therapeutic methods. An elevated level of GART is associated with poor outcomes in CRC patients and promotes the proliferation and migration of CRC cells. CD133+ cells with increased GART expression possess higher tumorigenic and proliferative capabilities both in vitro and in vivo. GART is identified to have a novel methyltransferase function, whose enzymatic activity center is located at the E948 site. GART also enhances the stability of RuvB‐like AAA ATPase 1 (RUVBL1) through methylating its K7 site, which consequently aberrantly activates the Wnt/β‐catenin signaling pathway to induce tumor stemness. Pemetrexed (PEM), a compound targeting GART, combined with other chemotherapy drugs greatly suppresses tumor growth both in a PDX model and in CRC patients. The present study demonstrates a novel methyltransferase function of GART and the role of the GART/RUVBL1/β‐catenin signaling axis in promoting CRC stemness. PEM may be a promising therapeutic agent for the treatment of CRC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Cells and Metastasis · Epigenetics and DNA Methylation · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine Nanjing University of Chinese Medicine Nanjing 210008 China

School of Medicine & Holistic Integrative Medicine Nanjing University of Chinese Medicine Nanjing 210046 China

School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210046 China

Department of Hematology and Oncology The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine Jinan 250001 China

Funding

National Natural Science Foundation of China · Priority Academic Program Development of Jiangsu Higher Education Institutions

References (100+)

Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.1136/gutjnl-2015-31091210.1136/gutjnl-2015-310912 ↗
3. 10.1200/JCO.21.0133210.1200/JCO.21.01332 ↗
4. 10.1158/1078-0432.CCR-19-302410.1158/1078-0432.CCR-19-3024 ↗
5. 10.1038/s41392-022-00889-010.1038/s41392-022-00889-0 ↗
6. 10.1016/j.stem.2011.02.02010.1016/j.stem.2011.02.020 ↗
7. 10.1007/s13238-011-1058-610.1007/s13238-011-1058-6 ↗
8. 10.1038/s41568-018-0056-x10.1038/s41568-018-0056-x ↗
9. 10.1038/nature0312810.1038/nature03128 ↗
10. 10.1038/nrc326110.1038/nrc3261 ↗
11. 10.1073/pnas.181821011610.1073/pnas.1818210116 ↗
12. 10.1002/1878-0261.1306410.1002/1878-0261.13064 ↗
13. 10.1016/j.biopha.2021.11136410.1016/j.biopha.2021.111364 ↗
14. Tsunekuni K. · Stem Cells Int · 2019 · 9
15. 10.1016/j.jsps.2020.09.00310.1016/j.jsps.2020.09.003 ↗
16. 10.3748/wjg.v17.i24.296510.3748/wjg.v17.i24.2965 ↗
17. 10.1182/blood.V90.12.500210.1182/blood.V90.12.5002 ↗
18. 10.1182/blood.V90.12.501310.1182/blood.V90.12.5013 ↗
19. 10.1007/s00441-004-1018-z10.1007/s00441-004-1018-z ↗
20. 10.1038/nrg184010.1038/nrg1840 ↗
21. 10.1111/jcmm.1488210.1111/jcmm.14882 ↗
22. 10.1128/MCB.01034-0710.1128/MCB.01034-07 ↗
23. 10.1016/j.celrep.2019.01.11010.1016/j.celrep.2019.01.110 ↗
24. 10.1038/s42003-021-01730-010.1038/s42003-021-01730-0 ↗
25. 10.1016/S0092-8674(00)81333-110.1016/S0092-8674(00)81333-1 ↗
26. 10.1093/jnci/djt37310.1093/jnci/djt373 ↗
27. 10.1182/blood.V89.9.335410.1182/blood.V89.9.3354 ↗
28. 10.1038/sj.leu.240165010.1038/sj.leu.2401650 ↗
29. 10.1073/pnas.040005310110.1073/pnas.0400053101 ↗
30. 10.1073/pnas.081328010610.1073/pnas.0813280106 ↗
31. 10.1098/rstb.2007.202610.1098/rstb.2007.2026 ↗
32. 10.3389/fmolb.2021.64764710.3389/fmolb.2021.647647 ↗
33. 10.21037/tlcr-20-46710.21037/tlcr-20-467 ↗
34. 10.1186/2051-5960-2-3110.1186/2051-5960-2-31 ↗
35. 10.1016/j.lfs.2016.10.02010.1016/j.lfs.2016.10.020 ↗
36. 10.3389/fonc.2021.72081410.3389/fonc.2021.720814 ↗
37. 10.4049/jimmunol.110309410.4049/jimmunol.1103094 ↗
38. 10.1073/pnas.152131611210.1073/pnas.1521316112 ↗
39. 10.1007/s00018-008-8295-810.1007/s00018-008-8295-8 ↗
40. 10.1107/S174430910902070310.1107/S1744309109020703 ↗
41. 10.1016/j.humpath.2013.11.02110.1016/j.humpath.2013.11.021 ↗
42. 10.1016/j.prp.2013.10.00910.1016/j.prp.2013.10.009 ↗
43. 10.1038/gt.2008.7110.1038/gt.2008.71 ↗
44. 10.1152/ajpcell.00177.201110.1152/ajpcell.00177.2011 ↗
45. 10.7150/ijbs.5145810.7150/ijbs.51458 ↗
46. 10.1016/j.devcel.2018.02.01010.1016/j.devcel.2018.02.010 ↗
47. 10.1158/0008-5472.CAN-18-284710.1158/0008-5472.CAN-18-2847 ↗
48. 10.1186/1741-7015-10-8510.1186/1741-7015-10-85 ↗
49. 10.1038/s41419-019-1712-010.1038/s41419-019-1712-0 ↗
50. 10.1200/JCO.2005.05.08110.1200/JCO.2005.05.081 ↗
51. 10.1083/jcb.20190207410.1083/jcb.201902074 ↗
52. 10.1021/acs.jmedchem.6b0059410.1021/acs.jmedchem.6b00594 ↗
53. 10.1186/s12943-019-1076-110.1186/s12943-019-1076-1 ↗
54. Zeng Y. · Dis Markers · 2022 · 2022
55. 10.1186/s13046-022-02465-410.1186/s13046-022-02465-4 ↗
56. 10.1136/gut.2006.09331010.1136/gut.2006.093310 ↗
57. 10.1136/gut.2004.06053310.1136/gut.2004.060533 ↗
58. 10.1158/0008-5472.CAN-21-126110.1158/0008-5472.CAN-21-1261 ↗
59. 10.7150/thno.2554110.7150/thno.25541 ↗
60. 10.1016/j.phymed.2020.15319110.1016/j.phymed.2020.153191 ↗
61. 10.1080/15476286.2021.195046410.1080/15476286.2021.1950464 ↗
62. 10.1053/j.gastro.2020.08.01610.1053/j.gastro.2020.08.016 ↗
63. 10.1002/ctm2.22510.1002/ctm2.225 ↗
64. 10.1111/resp.1209410.1111/resp.12094 ↗
65. 10.1155/2019/751263210.1155/2019/7512632 ↗
66. Jeng K. S. · Int. J. Mol. Sci. · 2023 · 24
67. 10.1038/s41388-020-01518-210.1038/s41388-020-01518-2 ↗
68. 10.1016/j.stem.2020.04.00810.1016/j.stem.2020.04.008 ↗
69. 10.1186/1471-2407-12-9610.1186/1471-2407-12-96 ↗
70. 10.1016/j.ejca.2009.04.00410.1016/j.ejca.2009.04.004 ↗
71. 10.1186/s12885-016-2879-810.1186/s12885-016-2879-8 ↗
72. 10.7150/ijbs.5861210.7150/ijbs.58612 ↗
73. 10.3892/ijo.2015.284410.3892/ijo.2015.2844 ↗
74. 10.1002/path.259710.1002/path.2597 ↗
75. 10.1111/jcmm.1428410.1111/jcmm.14284 ↗
76. 10.1080/2162402X.2020.184692610.1080/2162402X.2020.1846926 ↗
77. 10.1186/s40169-018-0198-110.1186/s40169-018-0198-1 ↗
78. 10.1021/acsami.6b0440310.1021/acsami.6b04403 ↗
79. Olsen C. E. · J Clin Med · 2019 · 9
80. 10.1016/j.canlet.2020.12.02210.1016/j.canlet.2020.12.022 ↗
81. Irollo E. · Am. J. Transl. Res. · 2013 · 5 · 563
82. 10.1016/j.ijrobp.2006.09.03710.1016/j.ijrobp.2006.09.037 ↗
83. 10.1016/j.canlet.2007.09.01210.1016/j.canlet.2007.09.012 ↗
84. 10.1093/nar/gkq59510.1093/nar/gkq595 ↗
85. 10.1016/j.phrs.2018.09.02710.1016/j.phrs.2018.09.027 ↗
86. 10.1002/jcb.3025110.1002/jcb.30251 ↗
87. 10.1007/s10495-016-1301-y10.1007/s10495-016-1301-y ↗
88. 10.1016/S2468-1253(20)30005-410.1016/S2468-1253(20)30005-4 ↗
89. 10.1007/s00018-015-2001-410.1007/s00018-015-2001-4 ↗
90. 10.1074/jbc.M80602020010.1074/jbc.M806020200 ↗
91. 10.1016/j.devcel.2013.05.02510.1016/j.devcel.2013.05.025 ↗
92. 10.1593/neo.1265610.1593/neo.12656 ↗
93. 10.1186/s13148-016-0240-310.1186/s13148-016-0240-3 ↗
94. 10.1038/nsmb.235310.1038/nsmb.2353 ↗
95. 10.1634/theoncologist.6-4-36310.1634/theoncologist.6-4-363 ↗
96. 10.1186/s12885-016-2117-410.1186/s12885-016-2117-4 ↗
97. 10.1007/s11523-017-0543-010.1007/s11523-017-0543-0 ↗
98. 10.21037/atm-20-109510.21037/atm-20-1095 ↗
99. 10.1016/j.ctrv.2008.10.00610.1016/j.ctrv.2008.10.006 ↗
100. 10.1007/s11605-011-1815-010.1007/s11605-011-1815-0 ↗